Module 5: Routes of Exposure–Dermal
Recorded On: 01/20/2020
The skin is the largest organ in the body by area, if not by weight, and is of great interest to toxicologists. In this presentation, we will consider the anatomy of the skin and topics such as metabolism, penetration of drugs, and toxicology and pharmacology, including the relationship between dermal drug application and systemic toxicity. The presentation will have a particular focus on drug delivery and aspects of purpose (not all dermally applied drugs are intended to have an effect in the skin), formulation/dosage forms, penetration, and kinetics. From a toxicological testing viewpoint, we will consider species selection (including selection of both non-rodent and rodent species in programme design strategies), and relevance to humans; study design and study performance will be discussed.
Andrew Makin, MSc
Consultant
Andrew Makin Preclinical Consulting ApS
Andrew Makin has almost 40 years of practical, hands-on experience in design, management, conduct and overview of preclinical programmes and individual studies. He has a first degree in biology and psychology from the University of Keele in England and an MSc in applied zoology from the University of Wales. He is a Member of the Royal Society of Biology and is a Registered Toxicologist. Dr. Makin’s experience in toxicology is in the areas of preclinical pharmaceutical development, and related subjects. He has a significant understanding of the scientific and regulatory requirements in these fields. Working in Contract Research, first in the UK with HLS from 1980 to 2001, and subsequently in Denmark from 2002 until 2019 with Scantox, LAB Research and Citoxlab, he has gained a very broad understanding of the needs of customers from a wide variety of different companies and approaches, from small (virtual) companies all the way up to Big Pharma. Dr. Makin’s work has involved all aspects of the process from identifying the needs of the customer through to execution of projects and interpretation of study results. During this time, he worked with most animal species and with most study types, and naturally, during his time at Scantox, this included a significant focus on the Göttingen minipig and projects involving the development of dermal and topical drugs and devices. Having worked with projects in all the major regions of the world, he has a fundamental understanding of the needs of drug development companies globally. Since 2019 he has taken this experience into the world of consulting, establishing his own company.